A study of genes and microRNAs that may predict clinical responses to anti-CTLA-4 therapy. This is an ASCO Meeting Abstract from the 2013 Genitourinary Cancers Symposium. This abstract does not ...
Cretostimogene for CIS-containing BCG unresponsive nonmuscle-invasive bladder cancer showed “best in class durability and tolerability,” according to investigators. Cretostimogene grenadenorepvec ...
The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), either with or without ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive data from the company’s late-stage bladder cancer trial ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months ...
Cross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide important context, particularly in the absence of head-to-head data, highlighting its efficacy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results